Allogene’s Donor-derived CAR T-cell Therapy Cleared for Clinical Testing on Non-Hodgkin’s Lymphoma
News
Allogene Therapeutics and its partner Servier will soon launch a Phase 1/2 trial to assess the investigational cell therapy ALLO-501 in non-Hodgkin’s lymphoma patients who failed prior therapies, after the U.S. Food and Drug ... Read more